ArticleCancer genomics & proteomics
TP53, PIK3CA, FBXW7 and KRAS Mutations in Esophageal Cancer Identified by Targeted Sequencing.
Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.
- No significant association between PIK3CA mutation and survival of esophageal squamous cell carcinoma: A meta-analysis.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2017Pooled it
- Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challenges.Signal transduction and targeted therapy · 2025Review
- Review
- Characterizing isoform switching events in esophageal adenocarcinoma.Molecular therapy. Nucleic acids · 2022Article
- Plasma Circulating Tumor DNA Sequencing Predicts Minimal Residual Disease in Resectable Esophageal Squamous Cell Carcinoma.Frontiers in oncology · 2021Article
- Targeted Therapies and Immunotherapies in the Treatment of Esophageal Cancers.Medical sciences (Basel, Switzerland) · 2019Review
- Genome-wide tracts of homozygosity and exome analyses reveal repetitive elements with Barrets esophagus/esophageal adenocarcinoma risk.BMC bioinformatics · 2019Article
- Relationship between esophageal cancer-related gene 2 polymorphism and esophageal squamous cell carcinomas in Kazakhs and Hans of Xinjiang.International journal of clinical and experimental pathology · 2019Article
- Article
- Current therapeutic landscape for advanced gastroesophageal cancers.Annals of translational medicine · 2018Review
- Molecular andF1000Research · 2018Article
- Article
- Molecular Characterization of Somatic Alterations in Dukes' B and C Colorectal Cancers by Targeted Sequencing.Frontiers in pharmacology · 2017Article
- Personalized and targeted therapy of esophageal squamous cell carcinoma: an update.Annals of the New York Academy of Sciences · 2016Review
- Educational Case: Barrett Esophagus.Academic pathologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors at 2 institutions in 1 country.
Funding
Abstract
BACKGROUND/
aimEsophageal cancer (EC) is a common malignancy with significant morbidity and mortality. As individual cancers exhibit unique mutation patterns, identifying and characterizing gene mutations in EC that may serve as biomarkers might help predict patient outcome and guide treatment. Traditionally, personalized cancer DNA sequencing was impractical and expensive. Recent technological advancements have made targeted DNA sequencing more cost- and time-effective with reliable results. This technology may be useful for clinicians to direct patient treatment. MATERIALS AND
methodsThe Ion PGM and AmpliSeq Cancer Panel was used to identify mutations at 737 hotspot loci of 45 cancer-related genes in 64 EC samples from Chinese patients.
resultsFrequent mutations were found in TP53 and less frequent mutations in PIK3CA, FBXW7 and KRAS.
conclusionThese results demonstrate that targeted sequencing can reliably identify mutations in individual tumors that make this technology a possibility for clinical use.
Indexed as
Identifiers
27107065PMC7495501W2341170336What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.